Orforglipron hype on TikTok: what the phase 3 data actually shows

What did @drmyramochi actually say?

The creator walked through Phase 2 trial data for orforglipron, an oral non-peptide GLP-1 receptor agonist being developed by Eli Lilly. The core claims: top-line weight loss of about 14.7% body weight over 36 weeks, over 90% of participants hitting at least 5% weight loss, no meal-timing restrictions unlike rybelsus (oral semaglutide), persistent GI side effects that don't improve the way they typically do with injectable GLP-1s, and a signal buried in the supplementary appendix around pulse rate increases. The creator was clear this is Phase 2 data, not an approved drug, and flagged that the pulse rate finding needs Phase 3 investigation. That framing deserves credit.

One note: the creator mispronounced several drug names throughout, including "zepochogovii" for tirzepatide and "ribellis" for rybelsus. Minor, but worth flagging in a medical communication context.

Does the science back this up?

Mostly, yes. The Phase 2 data referenced matches the results published by Wharton et al. (2023, NEJM), which reported up to 14.7% mean body weight reduction at 36 weeks in the highest dose cohorts of orforglipron compared to 2.3% placebo. Those numbers are real.

The "over 90% adverse event" figure is also accurate per the published data, where treatment-emergent adverse events were reported in 90% or more of participants in active dose groups, predominantly GI-related. The persistence of those side effects across the trial period, rather than the typical front-loading seen with semaglutide titration, was indeed flagged in the study. Husain et al. (2023, Lancet) noted similar GI persistence patterns in earlier orforglipron studies in type 2 diabetes populations.

The non-peptide structure claim is accurate. Orforglipron is a small molecule, which theoretically simplifies manufacturing. Whether that translates to lower cost for patients is genuinely unknown and the creator was honest about that uncertainty.

What did they get wrong (or right)?

The creator got the headline numbers right and the framing was appropriately cautious for Phase 2 data. That said, a few things needed more nuance.

Comparing 14.7% weight loss to semaglutide or tirzepatide without accounting for trial design differences is a stretch. The STEP 1 trial (Wilding et al., 2021, NEJM) used 68 weeks to achieve 14.9% with semaglutide 2.4mg. Orforglipron hit a similar number in 36 weeks but in a different population, with different dosing protocols and different endpoint structures. Cross-trial comparisons like this are notoriously unreliable and the creator glossed over that.

The pulse rate signal, described as a "post-rate increase" in the transcript (likely heart rate), was mentioned but underplayed. The Wharton et al. data showed mean increases in heart rate of around 5-7 bpm in higher dose groups. That is not a trivial finding, particularly for patients with pre-existing cardiovascular conditions. Calling it "interesting data" undersells a safety signal that Phase 3 needs to address seriously.

The no-meal-timing claim is accurate based on current Phase 2 protocols. Rybelsus requires a 30-minute fasting window before eating, which is a real adherence barrier.

What should you actually know?

Orforglipron is not approved. It is not available. Phase 2 trials are designed to establish dosing ranges and preliminary safety, not to confirm efficacy at scale. Phase 3 trials enroll thousands of participants and run longer. A drug can look promising in Phase 2 and fail or get significantly modified before approval.

The GI side effect persistence is a legitimate concern. With semaglutide and tirzepatide, most patients see nausea and GI symptoms front-loaded during titration, improving substantially by weeks 12-20. If orforglipron does not follow that pattern, adherence at 36 weeks and beyond could be a real problem in real-world use, not a controlled trial setting.

The heart rate signal needs watching. GLP-1 receptor agonists as a class are associated with modest heart rate increases. Combined with the cardiovascular benefit data from the SELECT trial (Lincoff et al., 2023, NEJM) for semaglutide, this is a complicated picture that Phase 3 data needs to sort out for orforglipron specifically.

Anyone currently on a GLP-1 medication should not interpret this video as a reason to wait, switch, or make changes to their treatment. That conversation belongs with a licensed provider who knows your full history.